From the publishers of JADPRO

Metastatic Triple-Negative Breast Cancer Resource Center

Advertisement
News & Literature Highlights

Cancer Discovery

Proteogenomic Markers of Chemotherapy Resistance and Response in Triple Negative Breast Cancer

Journal of Clinical Oncology

Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer

ESMO Congress 2022

Primary Endpoint Analysis of a Randomized Phase II Trial of Darolutamide or Capecitabine in Patients With Triple-Negative Androgen Receptor-Positive Advanced Breast Cancer (UCBG3-06 START Trial)

ESMO Congress 2022

Primary Endpoint Results of SYNERGY, a Randomized Phase II Trial, First-Line Chemo-Immunotherapy Trial of Durvalumab, Paclitaxel, and Carboplatin With or Without the Anti-CD73 Antibody Oleclumab in Patients With Advanced or Metastatic Triple-Negative Breast Cancer

ESMO Congress 2022

Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line Treatment for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer: Initial Results From BEGONIA, a Phase 1b/2 Study

PharmacoEconomics

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

Nature Reviews Clinical Oncology

Treatment Landscape of Triple-Negative Breast Cancer—Expanded Options, Evolving Needs

Medicine

Case Report of Long-Term Survival With Metastatic Triple-Negative Breast Carcinoma: Treatment Possibilities for Metastatic Disease

Physiological Reports

Diet Impacts Triple-Negative Breast Cancer Growth, Metastatic Potential, Chemotherapy Responsiveness, and Doxorubicin-Mediated Cardiac Dysfunction

Future Oncology

Real-World Effectiveness Outcomes in Patients Diagnosed With Metastatic Triple-Negative Breast Cancer

Advertisement
Advertisement